Sanofi India Limited has officially announced a significant leadership change. Mr. Rodolfo Hrosz, the Managing Director of the company, will be stepping down from his current role effective close of business on 30th April 2025. This decision is part of a planned internal movement within the Sanofi group, indicating a broader strategic shift in the organization.

Following his cessation as Managing Director, Mr. Hrosz will assume a new role as Non-Executive Director of Sanofi India starting 1st May 2025, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM).

Reason for the Change

The reason cited for the change in designation is an internal movement within the Sanofi group. Mr. Hrosz’s new responsibilities within the organization necessitate his stepping down from the Managing Director role of Sanofi India.

With this transition:

• He will cease to be a Key Managerial Personnel (KMP)

• He will no longer be a part of the Senior Management Team

• He will also relinquish his position in various Board Committees

Despite this change, the company confirmed that Mr. Hrosz will continue to be associated with Sanofi India, albeit in a non-executive capacity, ensuring continuity in leadership and strategic alignment.

Timeline of the Transition

The timeline of this leadership transition is clearly outlined:

• Last day as Managing Director: 30th April 2025

• First day as Non-Executive Director: 1st May 2025

The new role is subject to approval by members during the AGM, reflecting corporate governance protocols.

Compliance and Disclosures

Sanofi India has assured that all statutory requirements have been complied with:

• Mr. Hrosz is not disqualified or debarred by SEBI, Ministry of Corporate Affairs (MCA) or any statutory authority

• He shares no personal, financial or professional relationships with any other Directors of the company

This disclosure aligns with SEBI’s Listing Obligations and Disclosure Requirements (LODR) and highlights transparent corporate governance practices by the company.

About Rodolfo Hrosz

While a new profile has not been submitted as part of this announcement, Mr. Rodolfo Hrosz has served Sanofi India in a strategic and operational leadership capacity. During his tenure, Sanofi India has strengthened its position in the Indian pharmaceutical market and driven key innovations and business transformations.

Implications for Sanofi India

This leadership shift marks a transitional moment for Sanofi India:

• Ensures continuity: As Mr. Hrosz continues in a Non-Executive Director capacity, it supports strategic continuity

• Opportunity for new leadership: The change paves the way for the appointment of a new Managing Director, who can bring fresh perspectives

• Investor confidence: Transparent communication of leadership changes fosters investor trust and reflects a strong governance structure

Conclusion

The orderly transition of Mr. Rodolfo Hrosz from Managing Director to Non-Executive Director illustrates Sanofi India's commitment to internal mobility, succession planning, and regulatory compliance. It sets an example of smooth leadership transformation while ensuring that the company stays aligned with its long-term vision and operational consistency.

The proposed change, once approved by shareholders, will allow Mr. Hrosz to remain connected with Sanofi India and contribute strategically, even as he takes on new responsibilities within the broader Sanofi group.

The Upcoming IPOs in this week and coming weeks are Aten Papers & Foam.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.